<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168169">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01896999</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2013-01275</org_study_id>
    <secondary_id>NCI-2013-01275</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <secondary_id>E4412</secondary_id>
    <secondary_id>E4412</secondary_id>
    <secondary_id>U10CA180820</secondary_id>
    <secondary_id>U10CA021115</secondary_id>
    <nct_id>NCT01896999</nct_id>
  </id_info>
  <brief_title>Ipilimumab and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma</brief_title>
  <official_title>A Phase I Study With an Expansion Cohort of the Combination of Ipilimumab and Brentuximab Vedotin in Patients With Relapsed/Refractory Hodgkin Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase I trial studies the side effects and best dose of ipilimumab when given together
      with brentuximab vedotin in treating patients with relapsed or refractory Hodgkin lymphoma.
      Monoclonal antibodies, such as ipilimumab and brentuximab vedotin, can block cancer growth
      in different ways. Some block the ability of cancer cells to grow and spread. Others find
      cancer cells and help kill them or carry cancer-killing substances to them.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated dose (MTD) and dose limiting toxicities (DLT) of the
      combination of brentuximab vedotin and ipilimumab.

      SECONDARY OBJECTIVES:

      I. To evaluate complete response (CR) rate, partial response (PR) rate and overall response
      rate (ORR), for the combination of brentuximab vedotin and ipilimumab.

      II. To evaluate the duration of remission (DOR) to the combination of brentuximab vedotin
      and ipilimumab, and compare with the DOR achieved with the most recent prior systemic
      therapy.

      III. To evaluate the progression-free survival (PFS) and the overall survival (OS) in
      patients receiving the combination of brentuximab vedotin and ipilimumab.

      TERTIARY OBJECTIVES:

      I. To evaluate the ability of the combination of brentuximab and ipilimumab to alter tumor
      specific T cell immunity.

      II. To evaluate a panel of cytokine and T cell specific biomarkers from the peripheral blood
      as a potential immune signature of treatment response to therapy with brentuximab vedotin
      and ipilimumab for patients with relapsed / refractory Hodgkin lymphoma (HL).

      III. To evaluate using gene expression profiling (GEP) a signature of response to the novel
      combination of an antibody drug conjugate with immunomodulatory therapy.

      OUTLINE: This is a dose-escalation study of ipilimumab.

      Patients receive ipilimumab intravenously (IV) over 90 minutes on day 1 of courses 1-4, 8,
      12, and 16 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21
      days for up to 16 courses in the absence of disease progression or unacceptable toxicity.

      After completion of study treatment, patients are followed up for 3 years.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2014</start_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>MTD of the combination of brentuximab vedotin and ipilimumab defined as the highest dose level at which less than 33% patients experience a DLT, graded using National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) version 4.0</measure>
    <time_frame>21 days</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Upon completion of the trial, frequency of subjects experiencing toxicities will be tabulated. Toxicities will be assessed and graded according to CTCAE version 4.0 terminology. Exact 95% confidence intervals around the toxicity proportions will be calculated.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>CR rate, assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson et al.)</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reported along with the 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PR rate, assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson et al.)</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reported along with the 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR rate, assessed using the Revised Response Criteria for Malignant Lymphoma (Cheson et al.)</measure>
    <time_frame>Up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>Reported along with the 95% confidence intervals.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR</measure>
    <time_frame>From the documented beginning of response (CR or PR) to the time of relapse, assessed up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>DOR will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates. Descriptive statistics will be used to evaluate the DOR achieved with the protocol therapy and with the most recent prior systemic therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>From the date of study entry to the date of death, assessed up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>OS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS</measure>
    <time_frame>From entry onto study until lymphoma progression or death from any cause, assessed up to 3 years</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS will be estimated using Kaplan-Meier methodology. Greenwood's formula will be used to calculate 95% confidence intervals for the Kaplan-Meier estimates.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change in the percentage of activated T cells and natural killer cells</measure>
    <time_frame>Baseline (Time 1) to 9 weeks (Time 3, time of first re-staging)</time_frame>
    <safety_issue>No</safety_issue>
    <description>These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year vs. those who are event-free at one year will be evaluated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the percentages of activated T cells and natural killer cells</measure>
    <time_frame>Day 1 of course 2 (Time 2) or 9 weeks (Time 3) to up to 6 weeks after completion of study treatment (Time 4, end of study)</time_frame>
    <safety_issue>No</safety_issue>
    <description>These quantities of interest will be calculated for each patient and the Wilcoxon signed-rank test will be used to test for significant difference between the time points. Using the Wilcoxon rank sum test (two-sided type I error of 0.1), differences between those who progress or die within one year vs. those who are event-free at one year will be evaluated.</description>
  </other_outcome>
  <other_outcome>
    <measure>Pre- and post-treatment levels of cytokines and T cell specific biomarkers</measure>
    <time_frame>Baseline to up to 6 weeks after completion of study treatment</time_frame>
    <safety_issue>No</safety_issue>
    <description>Pre- and post-treatment levels of these markers will be compared using the Wilcoxon signed-rank test with two-sided type I error of 0.1. Marker levels between patients who fail at 1-year vs. patients who are event-free at 1-year will be evaluated. Given limited data, the analyses of PD-1, co-expression of Tim-3 with PD-1, ICOS, sCD30, galectin-1 and the peripheral blood absolute lymphocyte to monocyte ratio will be mainly exploratory and will be summarized descriptively at the time-points described above. The association with PFS will be explored.</description>
  </other_outcome>
  <other_outcome>
    <measure>Differentially expressed genes between two groups (patients who fail at 1-year vs. patients who are event-free at 1-year or responders vs. non-responders), assessed using GEP</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>Differentially expressed genes will be identified using a rank-based method developed by Dr. Hong (RankProd, R package, Bioconductor Project) with multiple comparison adjustment using a false discovery rate approach. A two-way unsupervised hierarchical clustering analysis will be applied to both the genes and the samples to illustrate whether GEP can separate two groups or is associated with other clinical factors. The genes ranked as most significant will be assessed by gene ontology and pathway analysis for their potential functions in lymphoma biology and treatment failure.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">27</enrollment>
  <condition>Recurrent Adult Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>Treatment (ipilimumab and brentuximab vedotin)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive ipilimumab IV over 90 minutes on day 1 of courses 1-4, 8, 12, and 16 and brentuximab vedotin IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 16 courses in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>ipilimumab</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ipilimumab and brentuximab vedotin)</arm_group_label>
    <other_name>anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody</other_name>
    <other_name>MDX-010</other_name>
    <other_name>MDX-CTLA-4</other_name>
    <other_name>monoclonal antibody CTLA-4</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (ipilimumab and brentuximab vedotin)</arm_group_label>
    <other_name>Adcetris</other_name>
    <other_name>anti-CD30 ADC SGN-35</other_name>
    <other_name>anti-CD30 antibody-drug conjugate SGN-35</other_name>
    <other_name>antibody-drug conjugate SGN-35</other_name>
    <other_name>SGN-35</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (ipilimumab and brentuximab vedotin)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients must have pathologically confirmed relapsed or refractory classical Hodgkin
             lymphoma (cHL); a biopsy at any relapse is acceptable; other histologies including
             lymphocyte predominant (LP) HL are not permitted

          -  Patients must have relapsed after first line chemotherapy; may have relapsed after
             autologous or allogeneic stem cell transplant, or have primary refractory disease; no
             upper limit for number of prior therapies; if status post allogeneic stem cell
             transplant, no active graft versus host disease

          -  Patients may have received prior brentuximab vedotin, but must not have received
             brentuximab vedotin within 6 months prior to registration, and must not have relapsed
             within 6 months of receiving previous brentuximab vedotin; patients may not have
             received prior ipilimumab

          -  Patients may have received other prior immunotherapies, but must not have received
             them within 6 months prior to registration, and there must be no serious unresolved
             complication of therapy at the time of registration

          -  Eastern Cooperative Oncology Group (ECOG)-American College of Radiology Imaging
             Network (ACRIN) performance status between 0-2

          -  Patients must have measurable disease; baseline measurements and evaluations must be
             obtained within 4 weeks of registration to the study; abnormal positron emission
             tomography (PET) scans will not constitute evaluable disease unless verified by a
             diagnostic quality computed tomography (CT) scan; patients must use the same imaging
             modality (CT or PET/CT) throughout the study

          -  Women must not be pregnant or breast-feeding; all females of childbearing potential
             must have a blood test or urine study within 2 weeks prior to registration to rule
             out pregnancy

          -  Women of childbearing potential and sexually active males must be strongly advised to
             use an accepted and effective method of contraception or to abstain from sexual
             intercourse for the duration of their participation in the study

          -  Patients must have no evidence of dyspnea at rest, no exercise intolerance, and a
             pulse oximetry &gt; 92% while breathing room air

          -  Patients must have forced expiratory volume in one second (FEV1)/forced vital
             capacity (FVC) &gt; 60% by pulmonary function test (PFT), unless due to large
             mediastinal mass from Hodgkin lymphoma (HL); carbon monoxide diffusion capacity
             (DLCO), FEV1, and FVC all &gt; 50% predicted value; all pulmonary function tests must be
             obtained within one month prior to registration

          -  Absolute neutrophil count (ANC) &gt;= 1500/mcL (1.5 x 10^9/L)

          -  Platelets &gt;= 75,000/mcL (75 x 10^9/L)

          -  Aspartate aminotransferase (AST)/alanine aminotransferase (ALT) =&lt; 2.5 x upper limit
             of normal (ULN)

          -  Bilirubin =&lt; 2 x ULN (unless documented Gilbert's syndrome, for which bilirubin =&lt; 3
             x ULN is permitted)

          -  Calculated creatinine clearance by Cockroft-Gault formula &gt;= 30 ml/min

          -  No evidence of prior malignancy except adequately treated non-melanoma skin cancer,
             in situ cervical carcinoma or any surgically- or radiation-cured malignancy
             continuously disease free for &gt;= 5 years so as not to interfere with interpretation
             of radiographic response

          -  Patient must have no current or prior history of central nervous system (CNS)
             involvement

          -  All prior therapy must have been completed at least 21 days prior to enrollment; no
             concomitant anti lymphoma therapy, including systemic corticosteroids for the purpose
             of treatment of lymphoma are allowed; topical steroids are allowed

          -  No history of Steven's Johnson's syndrome, toxic epidermal necrolysis (TENs)
             syndrome, or motor neuropathy

          -  Human immunodeficiency virus (HIV) positive patients are allowed on this study if
             they have a cluster of differentiation 4 (CD4) count &gt; 400, and are on a stable
             antiviral regimen; patients with poorly controlled HIV or other chronic active viral
             infections will be excluded

          -  Patients must not have autoimmune disorders or conditions of immunosuppression that
             require current ongoing treatment with systemic corticosteroids (or other systemic
             immunosuppressants), including oral steroids (i.e., prednisone, dexamethasone) or
             continuous use of topical steroid creams or ointments or ophthalmologic steroids; a
             history of occasional (but not continuous) use of steroid inhalers is allowed

               -  Replacement doses of steroids for patients with adrenal insufficiency are
                  allowed; patients who discontinue use of these classes of medication for at
                  least 2 weeks prior to randomization are eligible if, in the judgment of the
                  treating physician investigator, the patient is not likely to require resumption
                  of treatment with these classes of drugs during the study

               -  Exclusion from this study also includes patients with a history of symptomatic
                  autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis
                  [scleroderma], systemic lupus erythematosus, Sj√∂gren's syndrome, autoimmune
                  vasculitis [e.g., Wegener's granulomatosis]); motor neuropathy considered of
                  autoimmune origin (e.g., Guillain-Barre syndrome and Myasthenia Gravis); other
                  CNS autoimmune disease (e.g., poliomyelitis, multiple sclerosis); patients with
                  autoimmune hypothyroid disease or type I diabetes on replacement treatment are
                  eligible

          -  Patients must not have grade 2 or greater peripheral sensory neuropathy

          -  Patients must not have New York Heart Association (NYHA) class III or IV heart
             failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or
             electrocardiographic evidence of acute ischemia

          -  Patients must not have previously existing hypersensitivity to brentuximab vedotin or
             ipilimumab

          -  Patients must not have a serious medical or psychiatric illness likely to interfere
             with study participation

          -  Patients must not be participating in any other clinical trial or taking any other
             experimental medications within 21 days prior to registration

          -  Patients may not receive routine vaccination for infectious disease within 30 days of
             receiving ipilimumab however it is suggested that routine vaccinations, including
             seasonal influenza, be given at least 2 weeks prior to study treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Catherine Diefenbach</last_name>
    <role>Principal Investigator</role>
    <affiliation>Eastern Cooperative Oncology Group</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University Hospitals and Clinics</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ranjana H. Advani</last_name>
      <phone>650-725-6456</phone>
      <email>radvani@stanford.edu</email>
    </contact>
    <investigator>
      <last_name>Ranjana H. Advani</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jonathon B. Cohen</last_name>
      <phone>404-778-2214</phone>
      <email>jonathon.cohen@emory.edu</email>
    </contact>
    <investigator>
      <last_name>Jonathon B. Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University/Winship Cancer Institute</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jonathon B. Cohen</last_name>
      <phone>404-778-1868</phone>
    </contact>
    <investigator>
      <last_name>Jonathon B. Cohen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Indiana University Medical Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose M. Azar</last_name>
      <phone>317-278-6942</phone>
      <email>jazar@iupui.edu</email>
    </contact>
    <investigator>
      <last_name>Jose M. Azar</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University/Sidney Kimmel Cancer Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Richard F. Ambinder</last_name>
      <phone>410-955-8839</phone>
      <email>rambind1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Richard F. Ambinder</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephen M. Ansell</last_name>
      <phone>507-284-0923</phone>
      <email>Ansell.stephen@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Stephen M. Ansell</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Clinical Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016-4760</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine S. Diefenbach</last_name>
      <phone>212-731-5670</phone>
      <email>Catherine.Diefenbach@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Catherine S. Diefenbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University Langone Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Catherine S. Diefenbach</last_name>
      <phone>212-263-4434</phone>
      <email>prmc.coordinator@nyumc.org</email>
    </contact>
    <investigator>
      <last_name>Catherine S. Diefenbach</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Froedtert and the Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Timothy S. Fenske</last_name>
      <phone>414-805-4633</phone>
      <email>tfenske@mcw.edu</email>
    </contact>
    <investigator>
      <last_name>Timothy S. Fenske</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>July 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Cytotoxic T-lymphocyte antigen 4</mesh_term>
    <mesh_term>Immunoconjugates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
